Cargando…

Research Progress on PARP14 as a Drug Target

Poly-adenosine diphosphate-ribose polymerase (PARP) implements posttranslational mono- or poly-ADP-ribosylation modification of target proteins. Among the known 18 members in the enormous family of PARP enzymes, several investigations about PARP1, PARP2, and PARP5a/5b have been launched in the past...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Wei, Wu, Hong-Jie, Cao, Lu-Qi, Li, Hui-Jin, He, Chun-Xia, Zhao, Dong, Xing, Lu, Li, Peng-Quan, Jin, Xi, Cao, Hui-Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411704/ https://www.ncbi.nlm.nih.gov/pubmed/30890936 http://dx.doi.org/10.3389/fphar.2019.00172

Ejemplares similares

Progress in Research on Antitumor Drugs and Dynamic Changes in Skeletal Muscles
por: Xu, Ting, et al.
Publicado: (2022)

Progress of research on molecular targeted therapies for colorectal cancer
por: Huang, Shilin, et al.
Publicado: (2023)

Research progress of natural silk fibroin and the application for drug delivery in chemotherapies
por: Yu, Bin, et al.
Publicado: (2023)

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
por: Wang, Nannan, et al.
Publicado: (2022)

Research progress of ginseng in the treatment of gastrointestinal cancers
por: Ni, Baoyi, et al.
Publicado: (2022)

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis
por: Ma, Hongbo, et al.
Publicado: (2022)

Nϵ-Carboxymethyl-Lysine Deteriorates Vascular Calcification in Diabetic Atherosclerosis Induced by Vascular Smooth Muscle Cell-Derived Foam Cells
por: Xu, Sui-Ning, et al.
Publicado: (2020)

Research Progress of Pharmacogenomics in Drug-Induced Liver Injury
por: Shao, Qihui, et al.
Publicado: (2021)

Lonicerae Japonicae Caulis: a review of its research progress of active metabolites and pharmacological effects
por: Cao, Yu-Xia, et al.
Publicado: (2023)

Research progress on pleiotropic neuroprotective drugs for traumatic brain injury
por: Zhao, Qinghui, et al.
Publicado: (2023)

Editorial: Progresses in the Drug Treatment of Chronic Cardiopulmonary Diseases
por: Li, Xiaohui, et al.
Publicado: (2022)

Baseline lymphocyte and cholinesterase levels may be the predictors of chronic herbal drug–induced liver injury
por: Zeng, Zhan, et al.
Publicado: (2022)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
por: Du, Tingting, et al.
Publicado: (2022)

Editorial: Ovarian cancer-targeted medication: PARP inhibitors, anti-angiogenic drugs, immunotherapy, and more
por: Wang, Zhi-Bin, et al.
Publicado: (2023)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

Research progress on the anti-tumor effect of Naringin
por: He, Jing, et al.
Publicado: (2023)

Processing and Polyherbal Formulation of Tetradium ruticarpum (A. Juss.) Hartley: Phytochemistry, Pharmacokinetics, and Toxicity
por: Shan, Qi-yuan, et al.
Publicado: (2020)

Human PARP1 substrates and regulators of its catalytic activity: An updated overview
por: Zhu, Tao, et al.
Publicado: (2023)

Progress of potential drugs targeted in lipid metabolism research
por: Liang, Kai, et al.
Publicado: (2022)

Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges
por: Zhang, Xi, et al.
Publicado: (2022)

Molecular mechanism and research progress on pharmacology of ferulic acid in liver diseases
por: Shi, Yingying, et al.
Publicado: (2023)

Relationship Between the Structure and Immune Activity of Components From the Active Polysaccharides APS-II of Astragali Radix by Enzymolysis of Endo α-1,4-Glucanase
por: Li, Ke, et al.
Publicado: (2022)

Research advances in drug therapy of endometriosis
por: Shi, Jianyou, et al.
Publicado: (2023)

Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs
por: Li, Nana, et al.
Publicado: (2020)

PARP inhibitors combined with radiotherapy: are we ready?
por: Sun, Chen, et al.
Publicado: (2023)

Progress in Research on the Role of FGF in the Formation and Treatment of Corneal Neovascularization
por: Chen, Mengji, et al.
Publicado: (2020)

Research Progress of the Role of Anthocyanins on Bone Regeneration
por: Mao, Wei, et al.
Publicado: (2021)

The Top-100 Highly Cited Original Articles on Drug Therapy for Ventilator-Associated Pneumonia
por: Wang, Chao-Yang, et al.
Publicado: (2019)

Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer
por: Gao, Lili, et al.
Publicado: (2021)

Global publication trends and research trends of necroptosis application in tumor: A bibliometric analysis
por: Wu, Yun-Yun, et al.
Publicado: (2023)

Switching Between LC-ESI-MS/MS and EMIT Methods for Routine TDM of Valproic Acid in Pediatric Patients With Epilepsy: What Clinicians and Researchers Need to Know
por: Xia, Ying, et al.
Publicado: (2021)

Corrigendum: Research advances in drug therapy of endometriosis
por: Shi, Jianyou, et al.
Publicado: (2023)

Corrigendum: Research advances in drug therapy of endometriosis
por: Shi, Jianyou, et al.
Publicado: (2023)

Research Progress on Main Symptoms of Novel Coronavirus Pneumonia Improved by Traditional Chinese Medicine
por: Luo, Chuan-hong, et al.
Publicado: (2020)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
por: Qin, Hongyu, et al.
Publicado: (2023)

Evaluation of a Clinically Relevant Drug–Drug Interaction Between Rosuvastatin and Clopidogrel and the Risk of Hepatotoxicity
por: Ning, Chen, et al.
Publicado: (2021)

SMG9 Serves as an Oncogene to Promote the Tumor Progression via EMT and Wnt/β-Catenin Signaling Pathway in Hepatocellular Carcinoma
por: Jin, Xing, et al.
Publicado: (2021)

The Research Progress of Exosomes in Osteoarthritis, With Particular Emphasis on the Therapeutic Effect
por: Xian Bo, Shang, et al.
Publicado: (2022)

Editorial: Cancer neuroscience: Drug repurposing targeting the innervated niche
por: Jin, Ming-Zhu, et al.
Publicado: (2023)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ucl921veo8nl9u74pjph14lqjv